切换至 "中华医学电子期刊资源库"
高级检索
中华普通外科学文献(电子版)

中华普通外科学文献(电子版) ›› 2018, Vol. 12 ›› Issue (02) : 85 -89. doi: 10.3877/cma.j.issn.1674-0793.2018.02.004

所属专题： 文献；

论著

microRNA-21通过上皮间质转化促进胆管癌细胞侵袭转移的研究
曹良启1,†(), 李越1, 何南1, 魏章均1, 张大伟1, 杨学伟1   
  1. 1. 510260　广州医科大学附属第二医院肝胆外科
  • 收稿日期:2017-12-17 出版日期:2018-04-01
  • 通信作者: 曹良启
  • 基金资助:
    广东省自然科学基金项目(2015A030313466); 广东省科技计划项目(2014A020212326)

MicroRNA-21 promoting the invasion and metastasis of cholangiocarcinoma through epithelial-mesenchymal transition

Liangqi Cao1,†(), Yue Li1, Nan He1, Zhangjun Wei1, Dawei Zhang1, Xuewei Yang1   

  1. 1. Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou510260, China
  • Received:2017-12-17 Published:2018-04-01
  • Corresponding author: Liangqi Cao
  • About author:
    Corresponding author: Cao Liangqi, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

曹良启, 李越, 何南, 魏章均, 张大伟, 杨学伟. microRNA-21通过上皮间质转化促进胆管癌细胞侵袭转移的研究[J]. 中华普通外科学文献(电子版), 2018, 12(02): 85-89.

Liangqi Cao, Yue Li, Nan He, Zhangjun Wei, Dawei Zhang, Xuewei Yang. MicroRNA-21 promoting the invasion and metastasis of cholangiocarcinoma through epithelial-mesenchymal transition[J]. Chinese Archives of General Surgery(Electronic Edition), 2018, 12(02): 85-89.

目的

探讨microRNA-21（miR-21）对胆管癌RBE细胞侵袭转移能力的影响及其内在机制。

方法

miR-21及其抑制基因片段（miR-21i）通过慢病毒载体感染胆管癌RBE细胞，RT-PCR用于检测RBE细胞中miR-21表达；Transwell体外侵袭实验和细胞划痕试验用于检测RBE细胞侵袭及转移能力；Western blotting用于检测PTEN蛋白和上皮间质转化（EMT）特征性蛋白E-cadherin、N-cadherin、Vimentin表达情况。

结果

miR-21过表达促进RBE细胞侵袭和转移，miR-21低表达抑制RBE细胞的侵袭和转移。miR-21过表达能够降低PTEN蛋白和E-cadherin蛋白，增强N-cadherin和Vimentin蛋白的表达；转染miR-21i抑制基因组（miR-21i）组则有相反的效果，而转染空白基因组（对照组）相应蛋白表达无明显变化。

结论

miR-21起到癌基因的作用，可增强胆管癌细胞侵袭和转移能力，其机制是通过调节抑癌基因PTEN及改变EMT相关蛋白的变化。这些发现为胆管癌侵袭转移的分子机制提供新的科学依据。

关键词: 胆管肿瘤, 微RNAs, 基因，抑制, 上皮-间质转化, PTEN
Objective

To investigate the effect of microRNA-21 (miR-21) on the invasionand metastasis of cholangiocarcinoma RBE cells, as well as its underlying mechanisms.

Methods

Cholangiocarcinoma RBE cells were transfected miR-21 or miR-21 inhibitor (miR-21i) mediated in lentivirus. Reverse transcription polymerase chain reaction (RT-PCR) was used to examine the expression of miR21. Transwell chambers and wound-healing assay were applied to measure the invasive and metastatic effects of RBE cells. Western blotting analysis was used to assess the expression of PTEN protein and epithelial-mesenchymal transition (EMT) related proteins, including E-cadherin, N-cadherin, and Vimentin.

Results

The over-expression of miR-21 promoted invasion and metastasis of cholangiocarcinoma RBE cells, miR-21 inhibitor suppressed these effects. Furthermore, it has been found that the over-expression of miR-21 up-regulated PTEN and E-cadherin proteins, and down-regulated N-cadherin and Vimentin proteins. However, these data were not observed in the control group.

Conclusions

miR-21 acts as an oncogene, promotes invasion and metastasis of cholangiocarcinoma cells through PTEN and EMT. These findings provide new scientific basis.

Key words: Bile duct neoplasms, MicroRNAs, Genes, suppressor, Epithelial-mesenchymal transition, PTEN
图1 miR-21转染后在各组的表达情况　miR-21为miR-21过表达组；miR-21 NC为miR-21过表达空白对照组；RBE为无转染的RBE细胞组；miR-21i为转染miR-21抑制片段基因组；miR-21i NC为miR-21i空白对照组；与RBE细胞组比较，*P<0.05
图2 各组细胞的侵袭和迁移情况　A为细胞的侵袭能力（×100）；B为相对迁移细胞数；miR-21为miR-21过表达组；miR-21 NC为miR-21过表达空白对照组；RBE为无转染的RBE细胞组；miR-21i为转染miR-21抑制片段基因组；miR-21i NC为miR-21i空白对照组；与RBE细胞组比较，*P<0.05
图3 miR-21对EMT相关蛋白E-cadherin、N-cadherin及Vimentin表达的影响　miR-21为miR-21过表达组；miR-21 NC为miR-21过表达空白对照组；RBE为无转染的RBE细胞组；miR-21i为转染miR-21抑制片段基因组；miR-21i NC为miR-21i空白对照组
图4 miR-21对PTEN蛋白表达的影响　miR-21为miR-21过表达组；miR-21 NC为miR-21过表达空白对照组；RBE为无转染的RBE细胞组；miR-21i为转染miR-21抑制片段基因组；miR-21i NC为miR-21i空白对照组
[1]
Squadroni M, Tondulli L, Gatta G, et al. Cholangiocarcinoma[J]. Crit Rev Oncol Hematol, 2017, 116: 11-31.
[2]
Correa-Gallego C, Maddalo D, Doussot A, et al. Circulating plasma levels of microRNA-21 and microRNA-221 are potential diagnostic markers for primary intrahepatic cholangiocarcinoma[J]. PLoS One, 2016, 11(9): e0163699.
[3]
曹良启，王闯，薛平, 等. 15-脱氧-前列腺素J2激活过氧化物酶体增殖物激活受体信号抑制肝癌细胞侵袭转移的实验研究[J/CD]. 中华普通外科学文献(电子版), 2015, 9(5): 351-355.
[4]
Xiong B, Cheng Y, Ma L, et al. MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells[J]. Int J Oncol, 2013, 42(1): 219-228.
[5]
Zhou Y, Sheng B, Xia Q, et al. Association of long non-coding RNA H19 and microRNA-21 expression with the biological features and prognosis of non-small cell lung cancer[J]. Cancer Gene Ther, 2017, 24(8): 317-324.
[6]
He C, Dong X, Zhai B, et al. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway[J]. Oncotarget, 2015, 6(30): 28867-28881.
[7]
Xue H, Tian GY. MiR-429 regulates the metastasis and EMT of HCC cells through targeting RAB23[J]. Arch Biochem Biophys, 2018, 637: 48-55.
[8]
Huang Y, Chen Y, Lin X, et al. Clinical significance of SLP-2 in hepatocellular carcinoma tissues and its regulation in cancer cell proliferation, migration, and EMT[J]. Onco Targets Ther, 2017, 10: 4665-4673.
[9]
De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression[J]. Nat Rev Cancer, 2013, 13(2): 97-110.
[10]
Bao L, Yan Y, Xu C, et al. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways[J]. Cancer Lett, 2013, 337(2): 226-236.
[11]
Wang LJ, He CC, Sui X, et al. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN[J]. Oncotarget, 2015, 6(8): 5932-5946.
[12]
He Q, Cai L, Shuai L, et al. Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21[J]. Mol Carcinog, 2013, 52(4): 286-296.
[1] 李康, 冀亮, 赵维, 林乐岷. 自噬在乳腺癌生物学进展中的双重作用[J]. 中华乳腺病杂志(电子版), 2023, 17(04): 195-202.
[2] 贺敬龙, 孙炜, 高明宏, 谢伟, 姜骆永, 何琦非, 岳家吉. 外泌体非编码RNA在骨关节炎发病机制中的研究进展[J]. 中华关节外科杂志(电子版), 2023, 17(04): 520-527.
[3] 林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[4] 周东杰, 蒋敏, 范海瑞, 高玲玲, 孔祥, 卢丹, 王丽萍. 非编码RNA在卵泡发育成熟中作用及其机制的研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 387-393.
[5] 范伟强, 林师佈, 孙传伟, 宋奇锋, 李望, 符誉, 陈艾. 不同切除范围的Bismuth-Corlette Ⅲ、Ⅳ型腹腔镜肝门部胆管癌手术临床对比分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 423-426.
[6] 宋铭杰, 韩青雷, 李佳隆, 邵英梅. 内镜下晚期肝外胆管恶性肿瘤消融治疗研究现况[J]. 中华普外科手术学杂志(电子版), 2023, 17(03): 340-342.
[7] 潘冰, 吕少诚, 赵昕, 李立新, 郎韧, 贺强. 淋巴结清扫数目对远端胆管癌胰十二指肠切除手术疗效的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 608-612.
[8] 王楚风, 蒋安. 原发性肝癌的分子诊断[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 499-503.
[9] 李斌奎. 不可切除肝内胆管细胞癌的转化治疗[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 511-516.
[10] 田驹, 孙伯洋, 杨荣华, 赵向前. 术中意外发现肝外胆管绒毛管状腺瘤的外科处理经验：附两例报道并文献复习[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 567-571.
[11] 陈雪岩, 孟兴凯. 肝门空肠吻合术在肝门部胆管癌根治术中的应用价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 440-443.
[12] 吴周宇, 周宝勇, 李明. 基于PSM分析腹腔镜肝门部胆管癌根治术安全性[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 384-388.
[13] 王健东, 全志伟. 重视胆道恶性肿瘤化疗联合靶向免疫的综合治疗[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 125-130.
[14] 李卓群, 任冯刚, 王荣峰, 张东, 耿智敏, 吕毅, 仵正. 胆管癌局部治疗技术应用进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 153-156.
[15] 单季军, 李相成. 肝门部胆管癌术前减黄及其对手术安全性的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 157-161.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号